Article Title: Genetic and Pharmacologic Inhibition of the Chemokine Receptor CXCR2 Prevents Experimental Hypertension and Vascular Dysfunction
Figure Lengend Snippet: The CXCR2 inhibitor SB265610 alleviates hypertension, vascular inflammation, and fibrosis after angiotensin II infusion. A , Systolic blood pressure was measured by the noninvasive tail-cuff method in vehicle or SB265610-treated mice before ( C ) and after angiotensin II treatment (T, 490ng/kg/min). B , H E staining of thoracic aorta ( left ) and the wall thickness of each group were analyzed ( right ). Scale bar, 50 μm. C , Masson staining of thoracic aorta ( left ) and the percentage of fibrotic area were analyzed ( right ). Scale bar, 50 μm. D , Flow cytometry analysis of CD45 + cells, CD45 + CD11b + F4/80 + macrophages, and CD45 + CD3 + T cells in aortic lysates ( left ). The histograms indicate the percentage of gated cells ( right ). E , qPCR analysis of IL-1β, IL-6, TNF-α, CD68, VCAM-1, and COX-2 mRNA expression levels in the aorta. F , qPCR analysis of α-SMA, collagen I, and collagen III mRNA expression levels in the aorta. * P
Article Snippet: Single-cell suspensions were treated with Fc block, washed, and stained with CD45 V500, CD3 PE-CF594, CD11b APC-Cy7, Ly6G PE-Cy7, Ly6C V450, F4/80 APC, and CXCR2 PE and their homologous isotype-matched negative controls (BD, Franklin Lakes, NJ).
Techniques: Mouse Assay, Staining, Flow Cytometry, Cytometry, Real-time Polymerase Chain Reaction, Expressing